» Articles » PMID: 15650076

Expression of Type 2 Iodothyronine Deiodinase in Human Osteoblast is Stimulated by Thyrotropin

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2005 Jan 15
PMID 15650076
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid hormones play important roles in bone growth, development, and turnover. To exert its biological activity, T(4) needs to be converted to T(3) by iodothyronine deiodinase. In human thyroid gland as well as rat brown adipose tissue, type 2 iodothyronine deiodinase (D2) expression is regulated by a TSH receptor-cAMP-mediated mechanism. TSH receptor knockout mice demonstrated the direct effects of TSH on bone via TSH receptors found on osteoblast and osteoclast precursors. In the present study we investigated the possible expression and function of iodothyronine deiodinase and TSH receptors in human osteoblast-like osteosarcoma (SaOS-2) cells and normal human osteoblast (NHOst) cells. Iodothyronine deiodinase activity was detected in SaOS-2 cells and NHOst cells, and all of the characteristics of deiodinating activity were compatible with those of D2. Northern analysis demonstrated D2 mRNA expression in SaOS-2 cells and NHOst cells. D2 mRNA levels as well as D2 activities were rapidly increased by dibutyryl cAMP or forskolin in SaOS-2 cells and NHOst cells. TSH receptor mRNA was demonstrated in SaOS-2 cells and NHOst cells, and D2 mRNA and D2 activity were stimulated by TSH in both cells. In addition, all T(3) receptor isoforms were detected by RT-PCR in SaOS-2 cells and NHOst cells. The present results indicate the expression of functional TSH receptors and D2 in human osteoblasts and suggest previously unrecognized roles of TSH receptors and local T(3) production by D2 in the pathophysiology of human osteoblasts.

Citing Articles

IMPACT OF GRAVES' DISEASE AND ANTITHYROID DRUG THERAPY ON BONE MINERAL DENSITY - PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL RELEVANCE.

Mudri D, Kizivat T, Smolic M, Mihaljevic I, Smolic R, Lucic N Acta Clin Croat. 2023; 61(3):496-504.

PMID: 37492357 PMC: 10364114. DOI: 10.20471/acc.2022.61.03.15.


Thyroid-Stimulating Hormone Favors Runx2-Mediated Matrix Mineralization in HOS and SaOS2 Cells: An In Vitro and In Silico Approach.

Govindan R, El-Sherbiny M, Ibraheem K, Narasimhan S, Salama M, Ahmad F Molecules. 2022; 27(3).

PMID: 35163879 PMC: 8838199. DOI: 10.3390/molecules27030613.


Inherited Disorders of Thyroid Hormone Metabolism Defect Caused by the Dysregulation of Selenoprotein Expression.

Lee K, Shin Y, Lee S, Lee S Front Endocrinol (Lausanne). 2022; 12:803024.

PMID: 35126314 PMC: 8807339. DOI: 10.3389/fendo.2021.803024.


Concurrent TSHR mutations and DIO2 T92A polymorphism result in abnormal thyroid hormone metabolism.

Park E, Jung J, Araki O, Tsunekawa K, Park S, Kim J Sci Rep. 2018; 8(1):10090.

PMID: 29973617 PMC: 6031622. DOI: 10.1038/s41598-018-28480-0.


Prevalence, Predictive Factors, and Characteristics of Osteoporosis in Hyperthyroid Patients.

Ale A, Ogbera A, Ebili H, Adeyemo O, Afe T Int J Endocrinol. 2018; 2018:3540256.

PMID: 29849614 PMC: 5907485. DOI: 10.1155/2018/3540256.